Guluronic acid

Synonyms: G2013
Guluronic acid (G2013) 是一种口服有效的氧化应激调节剂与抗炎剂,能通过下调 TLR4、NF-κB、iNOS 等多种促炎及氧化应激相关基因并抑制 COX-2、MMPs 及 VEGF 的活性发挥药理作用,低剂量时可上调免疫调节基因 SHIP1 和 SOCS1 的表达,从而有效抑制癌症相关炎症、肿瘤血管生成、细胞黏附及转移并减少免疫抑制细胞的聚集,且在无直接细胞毒性的浓度范围内可显著延长荷瘤宿主的生存期、展现出良好的安全性,用于多发性硬化、强直性脊柱炎、乳腺癌及其他炎症性疾病的研究。
产品编号: MS-U09929 CAS No.: 15769-56-9 分子式: C6H10O7 分子量: 194.14
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
询价

产品描述

Guluronic acid (G2013) 是一种口服有效的氧化应激调节剂与抗炎剂,能通过下调 TLR4、NF-κB、iNOS 等多种促炎及氧化应激相关基因并抑制 COX-2、MMPs 及 VEGF 的活性发挥药理作用,低剂量时可上调免疫调节基因 SHIP1 和 SOCS1 的表达,从而有效抑制癌症相关炎症、肿瘤血管生成、细胞黏附及转移并减少免疫抑制细胞的聚集,且在无直接细胞毒性的浓度范围内可显著延长荷瘤宿主的生存期、展现出良好的安全性,用于多发性硬化、强直性脊柱炎、乳腺癌及其他炎症性疾病的研究。

生物实验数据

生物活性 Guluronic acid (G2013) is an orally effective oxidative stress modulator and anti-inflammatory agent that exerts its pharmacological effects by downregulating multiple pro-inflammatory and oxidative stress-related genes (such as TLR4, NF-κB, and iNOS) and inhibiting the activities of COX-2, MMPs, and VEGF; at low doses, it upregulates the expression of the immunoregulatory genes SHIP1 and SOCS1, thereby effectively suppressing cancer-related inflammation, tumor angiogenesis, cell adhesion, and metastasis while reducing the accumulation of immunosuppressive cells; within a concentration range devoid of direct cytotoxicity, it significantly prolongs the survival of tumor-bearing hosts, demonstrating a favorable safety profile, and is used in research on multiple sclerosis, ankylosing spondylitis, breast cancer, and other inflammatory diseases.
IC50 & Target

MMP-9

 

MMP-2

 

COX-2

 

TLR4

 

iNOS

 

体外研究
(In Vitro)

Guluronic acid (G2013) (25 μg/well;LPS 预孵育 4 h 后处理 18 h) 可显著抑制 LPS 诱导的健康人外周血单个核细胞 (PBMCs) 中 SOD2、GPX1、GST 及 MPO 的 mRNA 表达;显著抑制 LPS 诱导的上述细胞中 CAT 和 iNOS 的 mRNA 表达。
Guluronic acid (5 μg/well;24 h) 显著下调 TLR4、MyD88 和 NF-κB 的基因表达,并显著上调 SHIP1 和 SOCS1 的基因表达。
Guluronic acid (25-500 ng/mL;24 h, 48 h) 对 HEK-Blue hTLR4 细胞的 24 h IC50 为 125 μg/ml,对 4T1 小鼠乳腺癌细胞的增殖无显著影响。
Guluronic acid (25-500 μg/ml;48 h) 剂量依赖性地抑制 4T1 小鼠乳腺癌细胞中 MMP2 (活性降低 22-31%) 和 MMP9 (活性降低 28-44%) 的活性。
Guluronic acid (25-500 μg/ml;共孵育 24 h) 可使 J774 小鼠巨噬细胞中 LPS 诱导的 PG2E 生成量降低约 66%。

Cell Cytotoxicity Assay

Cell Line: HEK-Blue hTLR4 cells
Concentration: 200 ng/ml, 1 μg/ml, 5 μg/ml, 25 μg/ml, 125 μg/ml
Incubation Time: 24 h
Result: Showed concentration-dependent inhibitory effects on cell growth, with an IC50 of 125 μg/ml after 24 h treatment.
Exhibited no cytotoxic effect at concentrations below 125 μg/ml.

Real Time qPCR

Cell Line: HEK-Blue hTLR4 cells (untreated condition)
Concentration: 5 μg/well (low dose); 15 μg/well (high dose)
Incubation Time: 24 h
Result: Decreased TLR4 gene expression by 65% (low dose) and 41% (high dose), compared to control.
Decreased MyD88 gene expression by 82% (low dose) and 47% (high dose), compared to control.
Increased SHIP1 gene expression by 62% (low dose) and decreased it by 27% (high dose, non-significant), compared to control. Increased SOCS1 gene expression by 72% (low dose) and decreased it by 29% (high dose), compared to control.
Decreased NF-κB gene expression by 69% (low dose) and 49% (high dose, non-significant), compared to control.

ELISA Assay

Cell Line: J774 murine macrophage cells
Concentration: 25, 250, 500 μg/ml
Incubation Time: 24 h (co-incubated with LPS)
Result: Reduced PGE2 levels by ~66% across all tested concentrations compared to LPS-only treated cells.
体内研究
(In Vivo)

Guluronic acid (G2013) 可降低小鼠实验性自身免疫性脑脊髓炎的疾病严重程度、延缓发病并降低发病率。
Guluronic acid (50 mg/kg;腹腔注射;每 2 天 1 次;肿瘤接种后第 6 天至第 26 天) 以及 Guluronic acid (50 μg/ml;对 4T1 细胞进行体外 48 小时预处理后造模) 可抑制癌症相关炎症,将肿瘤生长抑制率最高提升至约 94.1%,消除经预处理细胞的转移能力,并延长同基因小鼠乳腺癌模型的生存期。

Animal Model: Breast cancer model in BALB/c (female, 6-8 weeks old, 18-20 g, syngeneic breast cancer model induced by 5×105 4T1 cell injection into mammary fat pad)
Dosage: 50 mg/kg (therapeutic group); 50 μg/ml (cell line pre-treated group)
Administration: i.p.; every 2 days; day 6 to day 26 post-tumor inoculation (therapeutic group); in vitro 48-hour pre-treatment of 4T1 cells before tumor inoculation (cell line pre-treated group)
Result: Reduced tumor volume by ~61.4% (therapeutic group) and ~94.1% (cell line pre-treated group) on day 30 post-inoculation compared to controls.
Exhibited metastasis incidence of 80% lung, 60% lymph node, and 20% liver (therapeutic group); showed no detectable metastasis in any organs (cell line pre-treated group).
Reduced lung metastatic area to ~5% per section (therapeutic group) and 0% (cell line pre-treated group) compared to ~15% in controls.
Lowered serum levels of IL-1β and IL-6 significantly in both groups; left TNF-α levels unchanged.
Reduced white blood cell count and granulocyte-to-lymphocyte ratio in both groups.
Reduced frequency of regulatory T cells (Treg) significantly in tumor tissue and lymph nodes (therapeutic group).
Reduced myeloid-derived suppressor cells (MDSC) significantly in tumor tissue and spleen (therapeutic group).
Reduced tumor angiogenesis by ~59.8% (therapeutic group) and ~91.1% (cell line pre-treated group) compared to controls.
Lowered tumor tissue mRNA expression of COX-2, MMP2, MMP9, and VEGF significantly in both groups compared to controls.
Prolonged survival significantly, with 100% of mice in the cell line pre-treated group surviving up to day 90, and higher survival rate in the therapeutic group than in controls.
性状 固体
颜色 White to off-white

化学信息

分子量 194.14
分子式 C6H10O7
CAS No. 15769-56-9
别名 G2013

储存&溶解度

储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 5 mg/mL (25.75 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM5.1509 mL25.7546 mL51.5092 mL128.7731 mL
5 mM1.0302 mL5.1509 mL10.3018 mL25.7546 mL
10 mM0.5151 mL2.5755 mL5.1509 mL12.8773 mL
15 mM0.3434 mL1.7170 mL3.4339 mL8.5849 mL
20 mM0.2575 mL1.2877 mL2.5755 mL6.4387 mL
25 mM0.2060 mL1.0302 mL2.0604 mL5.1509 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础